Enhanced PD‐L1 expression on tumor cells in primary cutaneous large T‐cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases

Takahashi, Emiko; Tsuchida, Takashi; Baba, Satoshi; Tsuzuki, Toyonori; Shimauchi, Takatoshi; Tokura, Y.; Tamada, Yasuhiko; Nakamura, Shigeo

doi:10.1111/pin.13000

Cited by 3 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous case report, enhanced nPD-L1 expression in nodal lesions (cases 1 and 2 in this series) appeared to co-occur with other aspects of CHL mimicry, in terms of morphology, immunophenotype, and the immune microenvironment containing abundant PD-L1 + TAMs and low-level PD-1 expression on T cells. 10 In all four cases of our series, nPD-L1 expression greatly increased with tumor progression to the lymph nodes, regardless of the presence or absence of CHL-like morphology. Contrastingly, the nodal lesions exhibited diffuse CD30 expression and an inflammatory TME, including abundant PD-L1 + TAMs and low-level PD-1 expression on T cells as observed in CHL.…”

Section: Discussionmentioning

confidence: 54%

“…The tumor cells had an HRS-like and/or lacunar cell appearance, and showed positivity for CD30 and CD15, mimicking nodular sclerosis CHL. 10 In contrast, in cases 3 and 4, nodal lesions did not cytopathologically mimic CHL. In the nodal lesions of case 3, medium-to-large-sized lymphoma cells exhibiting CD30 expression were scattered in a mixed inflammatory background ( Fig.…”

Section: Resultsmentioning

confidence: 83%

“…We recently reported two cases of secondary nodal lesions of CD30-positive primary cutaneous large T-cell lymphoma (PC-LTCL), which morphologically mimicked CHL. 10 Notably, both cases exhibited a substantial increase of nPD-L1 with tumor progression to lymph node involvement. In addition to morphological mimicking, the enhanced nPD-L1 expression in nodal lesions seemed to co-occur with other aspects of CHL mimicry in terms of both immunophenotype and the immune microenvironment, which comprised abundant PD-L1 + tumor-associated macrophages (TAMs) and low-level PD-1 expression on T lymphocytes.…”

Section: Introductionmentioning

confidence: 89%

“…Cases 1 and 2 were described in our previous report. 10 We retrospectively obtained clinical information, including laboratory and radiologic findings, and follow-up data. This study was approved by the Aichi Medical University Hospital Institutional Review Board (2020-192, 15/1/2021).…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases

Takahashi

Imai

Tsuyuki

et al. 2023

J Clin Exp Hematopathol

Self Cite

View full text Add to dashboard Cite

Scarce data are available regarding neoplastic PD-L1 (nPD-L1, clone SP142) expression in cutaneous T-cell lymphoma. We recently documented a possible association of increased nPD-L1 expression with tumor progression to secondary nodal involvement in two cases of CD30-positive primary cutaneous large T-cell lymphoma (PC-LTCL) (Pathol Int 2020;70:804). Notably, the nodal sites exhibited classic Hodgkin lymphoma (CHL) mimicry related to both morphology and tumor microenvironment (TME), i.e., abundant PD-L1-positive tumor-associated macrophages and low-level PD-1 expression on T-cells. Immunohistochemistry highlighted distinctly different nPD-L1 positivity between the cutaneous and nodal lesions. In the present study, we aimed to validate this unique phenomenon in a larger series of four cases with FISH and targeted-capture sequencing (targeted-seq) analysis. We retrospectively identified two more cases of CD30-positive PC-LTCL with secondary nodal involvement among all patients consecutively diagnosed between 2001-2021. All cases immunohistochemically exhibited elevated nPD-L1 expression on ≥50% of lymphoma cells in nodal tumors, clearly contrasting with the scarce nPD-L1 positivity (≤1%) in cutaneous tumors. Moreover, all nodal lesions exhibited CHL-like TME, with abundant PD-L1-positive tumor-associated macrophages and low-level PD-1 expression on T cells, although the CHL-like morphology was limited in the two original cases. None showed CD274/PD-L1 copy number alteration by FISH analysis, or structural variations of PD-L1 3'-UTR by targeted-seq analysis. These findings indicated that nPD-L1 expression is linked with tumor progression and CHL-like TME in nodal involvement of PC-LTCL. Interestingly, one autopsied case exhibited heterogeneity of nPD-L1 expression at different disease sites.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Resultsmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 89%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases

Takahashi

Imai

Tsuyuki

et al. 2023

J Clin Exp Hematopathol

Self Cite

View full text Add to dashboard Cite

show abstract

“…subsequent development of pcCD30 + LPD with anaplastic-like or HRS-like morphology where both initial and transformed lesions shared the same clone [15][16][17][18][19][20][21][22][23] (Table 1). Additional genomic studies such as ALK and DUSP22 rearrangements, chromosome analysis, or NGS were performed in some cases, which supported the nature of transformation.…”

Section: Discussionmentioning

confidence: 99%

Anaplastic Large Cell Transformation of Mycosis Fungoides: Case Report and Review of the Literature

Flerova,

Alpdogan,

Bhatti

et al. 2023

The American Journal of Dermatopathology

View full text Add to dashboard Cite

We report a 48-year-old man with CD30+ large cell transformation of mycosis fungoides (tMF) with distinctive anaplastic morphology. The patient initially presented with folliculotropic and syringotropic mycosis fungoides (MF) manifested as occipital scalp plaque and trunk and extremities patches. Six years later, he progressed to the tumor stage from his scalp lesion and developed cervical lymphadenopathy. Lymph node and scalp biopsies showed diffuse infiltration of CD30+ anaplastic cells with multinucleated, hallmark-like, Hodgkin–Reed–Sternberg-like, histiocytoid forms, indistinguishable from anaplastic large cell lymphoma (ALCL). T-cell receptor gamma gene (TCRg) rearrangement studies revealed identical clones in the initial MF scalp lesion and nodal anaplastic lesion, confirming the transformation. Ancillary studies showed absence of IRF4/DUSP22 and ALK rearrangements and positive RB1, SMARCA4, SOCS1, and TP53 mutations. The patient achieved partial response with systemic chemotherapy. Our case is an example of tMF presenting as the morphology and phenotype of ALCL. Because clinical behavior and therapeutic options of tMF and primary cutaneous ALCL may be different, it is clinically relevant to differentiate these 2 entities. The proof of clonal relationship may be useful in diagnostically challenging cases with features overlapping between tMF and primary cutaneous ALCL.

show abstract

Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art

Zanelli,

Fragliasso,

Parente

et al. 2024

IJMS

View full text Add to dashboard Cite

The interaction of programmed death-1 (PD-1) on T lymphocytes with its ligands Programmed Death Ligand 1 (PD-L1) and Programmed Death Ligand 2 (PD-L2) on tumor cells and/or tumor-associated macrophages results in inhibitory signals to the T-cell receptor pathway, consequently causing tumor immune escape. PD-L1/PD-L2 are currently used as predictive tissue biomarkers in clinical practice. Virtually PD-L1 levels expressed by tumor cells are associated with a good response to immune checkpoint blockade therapies targeting the PD-1/PD-L1 axis. These therapies restore T-cell antitumor immune response by releasing T-lymphocytes from the inhibitory effects of tumor cells. Immune checkpoint therapies have completely changed the management of patients with solid cancers. This therapeutic strategy is less used in hematological malignancies, although good results have been achieved in some settings, such as refractory/relapsed classic Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Variable results have been obtained in diffuse large B-cell lymphoma and T-cell lymphomas. Immunohistochemistry represents the main technique for assessing PD-L1 expression on tumor cells. This review aims to describe the current knowledge of PD-L1 expression in various types of lymphomas, focusing on the principal mechanisms underlying PD-L1 overexpression, its prognostic significance and practical issues concerning the evaluation of PD-L1 immunohistochemical results in lymphomas.

show abstract

Enhanced PD‐L1 expression on tumor cells in primary cutaneous large T‐cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases

Cited by 3 publications

References 17 publications

Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases

Enhanced PD-L1 expression on tumor cells in primary CD30-positive cutaneous large T-cell lymphoma: a report of lymph node lesions of four cases

Anaplastic Large Cell Transformation of Mycosis Fungoides: Case Report and Review of the Literature

Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art

Contact Info

Product

Resources

About